By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roche today reported that its molecular diagnostics sales increased 4 percent year over year, while its sales for microarrays and genomic sequencing products dropped sharply.

The Swiss pharmaceuticals, diagnostics, and research products giant also issued another statement saying that its $51-per-share offer to acquire Illumina is "full, fair, and extremely attractive by every conceivable metric."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.